Gastrointestinal
Gastroparesis & GI Dysmotility
Read MoreTherapeutic Applications
A Multi-Disease Therapeutic Platform
CgA Therapeuticals is developing catestatin (CST) and next-generation CST-based peptides and peptidomimetics as potential therapeutics for diseases involving dysregulated neuroendocrine signaling, inflammation, metabolism, gastrointestinal function, cardiovascular homeostasis, and neurodegeneration.
CST is an endogenous regulatory peptide with pleiotropic biological actions. Rather than acting on a single disease-associated target, CST influences multiple interconnected pathways involved in maintaining physiological homeostasis. This provides the scientific foundation for a platform-based therapeutic strategy spanning several areas of unmet medical need.
Advantages of Next-Generation CST Therapeutics
Native CST has potent biological activity but, like many endogenous peptides, has a relatively short circulating half-life. CgA Therapeuticals is therefore developing next-generation CST analogs and peptidomimetics designed to improve stability, pharmacokinetics, therapeutic exposure, and dosing characteristics.
One lead candidate is retro-inverso CST (RI-CST), which incorporates a reversed peptide sequence composed of D-amino acids, providing increased resistance to proteolytic degradation. Our preclinical studies demonstrate that RI-CST has a substantially prolonged pharmacokinetic profile compared with native CST while retaining biological activity.
The broader development platform includes native CST, naturally occurring human CST variants, RI-CST, D-amino-acid derivatives, and additional peptide and peptidomimetic candidates. Candidate selection is based not simply on stability, but on an integrated assessment of biological activity, efficacy, pharmacokinetics, safety, tissue exposure, manufacturability, and formulation potential.
From Preclinical Discovery Toward Clinical Translation
CgA Therapeuticals' development strategy is designed to systematically advance promising CST-based candidates from preclinical proof-of-concept through lead optimization, pharmacology and toxicology, formulation and manufacturing development, and ultimately, regulatory evaluation for human clinical studies.
The company's exclusive therapeutic license covering defined UC San Diego patent rights provides an intellectual-property foundation for the development and commercialization of CST-related therapeutic technologies. The licensed portfolio includes inventions spanning cardiometabolic disease, neurodegeneration and cognitive decline, and oncology, subject to the terms of the license and applicable government rights.
The development framework anticipates progression through preclinical toxicology, formulation and manufacturing development, regulatory submission, and subsequent clinical development.
CST, RI-CST, and other CST-based therapeutic candidates are investigational. They have not been approved by the U.S. Food and Drug Administration for the treatment of gastroparesis, Alzheimer's disease, cardiometabolic disease, cancer, or any other condition.